Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis

Annals of Allergy, Asthma and Immunology

Volumn 90, Issue 2, 2003, Pages 214-222

  Van Adelsberg, Janet ^a,d   Philip, George ^a   LaForce, Craig F ^b   Weinstein, Steven F ^c   Menten, Joris ^a   Malice, Marie Pierre ^a   Reiss, Theodore F ^a   Banov, Charles H ^d   Bardelas, Jose A ^d   Charlton, Scott A ^d   Chervinsky, Paul ^d   Coutin, David B ^d   Finn, Albert F ^d   Fisher Jr , Chester L ^d   Given, John Thomas ^d   Kaiser, Harold B ^d   Larsen, Lawrence V ^d   Lumry, William R ^d   Maccia, Clement A ^d   Meltzer, Eli O ^d   Nayak, Anjuli S ^d   Nayak, Nicholas A ^d   Pedinoff, Andrew J ^d   Picone, Frank J ^d   Ratner, Paul H ^d   Rooklin, Anthony R ^d   Rowe, Michael S ^d   Segal, Allen T ^d   Tripathy, Ita ^d   Van Bavel, Julius ^d   Cheema, Amarjit S ^d   Hébert, Jacques R ^d   Houle, Pierre Alain ^d   Keith, Paul Kevin ^d   Moote, William D ^d   Patel, Piyush ^d   Yang, William H ^d   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b North Carolina Clinical Research   (United States)

^c Allerg Asthma Specialists Med Grp   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

LORATADINE; MONTELUKAST; PLACEBO;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; SEASONAL VARIATION; SIDE EFFECT; SPRING; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0037326761     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62144-8     Document Type: Article

References (37)

1. Simons FE. Allergic rhinobronchitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol 1999;104:534-540.
2. Meltzer EO. Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of "one linked airway disease." Ann Allergy Asthma Immunol 2000;84:176-187.
3. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(Suppl):S147-S334.
4. American Thoracic Society Workshop. Immunobiology of asthma and rhinitis. Pathogenic factors and therapeutic options. Am J Respir Crit Care Med 1999;160:1778-1787.
5. Lam S, Chan H, LeRiche JC, et al. Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol 1988;81:711-717.
6. 4 release in upper respiratory mucosa during natural exposure to ragweed in ragweed-sensitive children. J Allergy Clin Immunol 1988;82:414-418.
7. Liu MC, Hubbard WC, Proud D, et al. Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes. Am Rev Respir Dis 1991;144:51-58.
8. Creticos PS, Peters SP, Adkinson NF Jr, et al. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl J Med 1984;310:1626-1630.
9. 4 in grass pollen-induced rhinitis. Am Rev Respir Dis 1987;136:357-362.
10. Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol 1996;98:1-13.
11. 4 and granulocytic infiltration into asthmatic airways. Lancet 1993;341:989-990.
12. 4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy 1986;16:289-297.
13. 4 in allergic rhinitis. Ann Allergy 1988;60:537-540.
14. Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998;158:1213-1220.
15. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Group. J Am Med Assoc 1998;279:1181-1186.
16. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001;108:E48.
17. Philip G, Malmstrom K, Hampel FC, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002;32:1020-1028.
18. Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 2000;105:917-922.
19. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21:77-83.
20. McNicholas, Tarlo S, Cole P, et al. Obstructive apneas during sleep in patients with seasonal allergic rhinitis. Am Rev Respir Dis 1982;126:625-628.
21. Juniper EF. Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol 1997;99:S742-S749.
22. Thompson AK, Juniper E, Meltzer EO. Quality of life in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2000;85:338-347.
23. Nayak AS, Philip G, Lu S, et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002;88:592-600.
24. Frick WE, Sedgwick JB, Busse WW. Hypodense eosinophils in allergic rhinitis. J Allergy Clin Immunol 1988;82:119-125.
25. Bhandari CM, Baldwa VS. Relative value of peripheral blood, secretion and tissue eosinophilia in the diagnosis of different patterns of allergic rhinitis. Ann Allergy 1976;37:280-284.
26. Pizzichini E, Leff JA, Reiss TF, et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 1999;14:12-18.
27. Volovitz B, Tabachnik E, Nussinovitch M, et al. Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma. J Allergy Clin Immunol 1999;104:1162-1167.
28. Haria M, Fitton A, Peters DH. Loratadine: a reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs 1994;48:617-637.
29. Allergic rhinitis: clinical development programs for drug products. Center for Drug Evaluation and Research, Food and Drug Administration, US Department of Health and Human Services. Rockville, MD: Office of Training and Communications, Division of Communications Management, Drug Information Branch; April 2000.
30. Frenz DA. Interpreting atmospheric pollen counts for use in clinical allergy: allergic symptomology. Ann Allergy Asthma Immunol 2001;86:150-157.
31. Corren J. The impact of allergic rhinitis on bronchial asthma. J Allergy Clin Immunol 1998;101(Suppl):S352-S356.
32. Grossman J. One airway, one disease. Chest 1997;111(Suppl):11S-16S.
33. Greisner WA III, Settipane GA. Co-exisistence of asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Asthma Proc 1998;19:185-188.
34. Howarth PH. Leukotrienes in rhinitis. Am J Respir Crit Care Med 2000;161:S133-S136.
35. Barnes PJ. Anti-leukotrienes: a new treatment for asthma. The Practitioner 1998;242:395-399.
36. Wilson AM, Orr LC, Sims EJ, Lipworth BJ. Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy 2001;31:61-68.
37. Wilson AM, Orr LC, Coutie WJ, et al. A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. Clin Exp Allergy 2002;32:126-132.